DNMT1 and myelodysplastic syndrome: At present, two types of DNA methyltransferase (DNMT) inhibitors, including 5-azacytidine and decitabine, have been approved by the US FDA to treat myelodysplastic syndromes (MDS) and bone marrow acute myeloid leukemia (AML).